Identification of Hub Genes and Pathways in Glioblastoma by Bioinformatics Analysis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jan 19

PMID 30655863

Citations 6

Authors

Shoubo Yang

Kaidi Gao

Wenbin Li

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most common type of malignant brain tumor, and is associated with poor patient prognosis. A comprehensive understanding of the molecular mechanism underlying GBM may help to guide the identification of novel diagnoses and treatment targets. The gene expression profile of the GSE4290 GBM dataset was analyzed in order to identify differentially expressed genes (DEGs). Enriched pathways were identified through Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analyses. A protein-protein interaction network was constructed in order to identify hub genes and for module analysis. Expression and survival analyses were conducted in order to screen and validate critical genes. A total of 1,801 DEGs were recorded, including 620 upregulated and 1,181 downregulated genes. Upregulated DEGs were enriched in the terms 'mitotic cell cycle process', 'mitotic cell cycle' and 'cell cycle process'. Downregulated genes were enriched in 'transsynaptic signaling', 'anterograde transsynaptic signaling' and 'synaptic signaling'. A total of 15 hub genes, which displayed a high degree of connectivity, were selected. These genes included vascular endothelial growth factor A, cyclin-dependent kinase 1 (CDK1), cell-division cycle protein 20 (CDC20), aurora kinase A (AURKA), and budding uninhibited by benzimidazoles 1 (BUB1). The identified DEGs and hub genes may help guide investigations on the mechanisms underlying the development and progression of GBM. CDK1, CDC20, AURKA and BUB1, which are involved in cell cycle pathways, may be potential targets in the diagnosis and therapy of GBM.

Citing Articles

Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches.

Sarker A, Aziz M, Hossen M, Mollah M, Al-Amin , Haque Mollah M Sci Rep. 2024; 14(1):27545.

PMID: 39528802 PMC: 11554889. DOI: 10.1038/s41598-024-79391-2.

SERPINE1 and its co-expressed genes are associated with the progression of clear cell renal cell carcinoma.

Guo L, An T, Wan Z, Huang Z, Chong T BMC Urol. 2023; 23(1):43.

PMID: 36959648 PMC: 10037920. DOI: 10.1186/s12894-023-01217-6.

IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma.

Swan S, Mehta N, Ilich E, Shen S, Wilkinson D, Anderson A Front Immunol. 2023; 14:1085547.

PMID: 36817432 PMC: 9936235. DOI: 10.3389/fimmu.2023.1085547.

Yu Y, Sung S, Lee C, Ha M, Kang J, Kwon E Front Genet. 2021; 12:743786.

PMID: 34646310 PMC: 8502821. DOI: 10.3389/fgene.2021.743786.

Scouting for common genes in the heterogenous hypoxic tumor microenvironment and their validation in glioblastoma.

Bhushan A, Kumari R, Srivastava T 3 Biotech. 2021; 11(10):451.

PMID: 34631352 PMC: 8473528. DOI: 10.1007/s13205-021-02987-2.

References

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

Fueyo J, Gomez-Manzano C, Alemany R, Lee P, McDonnell T, Mitlianga P . A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000; 19(1):2-12. DOI: 10.1038/sj.onc.1203251. View

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Cantrell D . Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001; 114(Pt 8):1439-45. DOI: 10.1242/jcs.114.8.1439. View

Fueyo J, Gomez-Manzano C, Liu T, Yung W . Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol. 2001; 51(3):277-87. DOI: 10.1023/a:1010661131403. View

Ashcroft M, Ludwig R, Woods D, Copeland T, Weber H, MacRae E . Phosphorylation of HDM2 by Akt. Oncogene. 2002; 21(13):1955-62. DOI: 10.1038/sj.onc.1205276. View

Behin A, Hoang-Xuan K, Carpentier A, Delattre J . Primary brain tumours in adults. Lancet. 2003; 361(9354):323-31. DOI: 10.1016/S0140-6736(03)12328-8. View

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

Bellail A, Hunter S, Brat D, Tan C, Van Meir E . Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004; 36(6):1046-69. DOI: 10.1016/j.biocel.2004.01.013. View

10.

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

11.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

12.

Sun L, Hui A, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S . Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006; 9(4):287-300. DOI: 10.1016/j.ccr.2006.03.003. View

13.

Davis S, Meltzer P . GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7. DOI: 10.1093/bioinformatics/btm254. View

14.

Kaynar M, Sanus G, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P . Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci. 2008; 15(9):1036-42. DOI: 10.1016/j.jocn.2007.07.080. View

15.

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

16.

Ulrich T, de Juan Pardo E, Kumar S . The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res. 2009; 69(10):4167-74. PMC: 2727355. DOI: 10.1158/0008-5472.CAN-08-4859. View

17.

Wong M, Prawira A, Kaye A, Hovens C . Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009; 16(9):1119-30. DOI: 10.1016/j.jocn.2009.02.009. View

18.

Kang S, Han K, Ku B, Lee Y, Hong J, Shin H . Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res. 2010; 70(3):1173-83. PMC: 3273964. DOI: 10.1158/0008-5472.CAN-09-2886. View

19.

Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman D . Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat. 2010; 129(3):777-84. DOI: 10.1007/s10549-010-1273-5. View

20.

Jiao X, Sherman B, Huang D, Stephens R, Baseler M, Lane H . DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012; 28(13):1805-6. PMC: 3381967. DOI: 10.1093/bioinformatics/bts251. View